Language
Western In-Licensing Deals with Chinese Companies: Focus on Disease Areas and Drug Types
, In-licensing deals, Chinese pharmaceutical companies, Western pharmaceutical companies, Disease areas, Drug types, Cross-border partnerships, Biopharma, Licensing trends,
Italian Antitrust Agency Investigates Novartis, Biogen, and Others Over Lucentis Biosimilar
Italian Competition Authority, Novartis, Biogen, Samsung Bioepis, Genentech, Lucentis, Byooviz, Biosimilar, Antitrust Probe
Eisai and Biogen Overcome Filing Hitch, Initiate FDA Submission for Subcutaneous Leqembi
Eisai, Biogen, FDA submission, Leqembi, subcutaneous, Alzheimer’s disease, rolling submission, BLA, clinical trials, monoclonal antibody, amyloid beta, neurodegenerative disorder
Novartis to Revise CRO Partnerships Amidst US Senate Bill Scrutiny
Novartis, CRO relationships, US Senate bill, Chinese companies, pharmaceutical industry, regulatory changes, partnership revisions
FTC’s Proposed Noncompete Ban: A Game Changer for Biopharma Job Mobility
FTC, Noncompete Ban, Biopharma Jobs, Job Mobility, Employee Rights, Competition Law
Fujifilm Diosynth Announces $1.2B Expansion in North Carolina, Aiming to Employ 1,400
Fujifilm Diosynth Biotechnologies, $1.2 billion expansion, North Carolina, Holly Springs, 1/400 jobs, Biopharmaceutical manufacturing, End-to-end cell culture CDMO facility, Japanese investment
Daiichi Sankyo Invests $1 Billion to Expand German Facility for Precision Cancer Antibody-Drug Conjugates
Daiichi, Sankyo, Antibody-Drug Conjugates